Ryan Ivey focuses his practice in the life sciences industry. Before joining Snell & Wilmer, Ryan worked for a biotechnology company, supporting executives and operating teams in transactional matters related to the outsourcing of drug discovery and clinical trial initiatives. Earlier, Ryan served as in-house counsel for a multinational contract research organization (CRO), advising on a wide range of legal, commercial and operational matters related to the performance of all phases of outsourced clinical trials of pharmaceuticals, biologics and medical devices.
Advised global contract research organization (CRO) in the negotiation of high-value clinical trial services transactions, including advising on more than 500 agreements with biopharmaceutical manufacturers and developers, ranging from confidentiality agreements to letters of intent and master services agreements for the performance of global, late-phase clinical trial services.
Assisted quality assurance and regulatory affairs subject-matter experts in the triage, investigation, analysis and reporting decisions relating to breaches of good clinical practices (GCP) in clinical trials.
Represented software provider in multiple high-value transactions with biopharmaceutical companies for the cloud-based access (SaaS) to provider’s proprietary platform of clinical trial design, clinical data capture and clinical analytics technologies.
Advised medical research facility on state and federal informed consent laws pertaining to human clinical research in connection with the facility’s oversight, review and approval duties regarding clinical trial documentation via its institutional review board (IRB).
Advised enterprise resource planning (ERP) software provider in the negotiation of multi-module master SaaS agreements.
Represented acquirer of medical device assets in due diligence and asset purchase agreement review with distribution and supply chain.
Assisted in the representation of biotechnology companies in the licensing of patents and other intellectual property from universities in the United States to enable collaboration in early-stage drug and/or medical device development.
Assisted in the representation of a non-profit cancer research center in the establishment of material transfer agreements, clinical trial agreements, advisory board agreements and governance policies with various stakeholders and collaborators.
Wake Forest University School of Law (J.D., 2015)
University of North Carolina at Wilmington (B.A., Political Science, 2012)